NCT03037086 (MEDI-APEX) is a clinical trial in Locally Advanced or Metastatic NSCLC, sponsored by AstraZeneca.

Who is sponsoring NCT03037086?

NCT03037086 is sponsored by AstraZeneca.

What condition does NCT03037086 study?

NCT03037086 studies Locally Advanced or Metastatic NSCLC.

Is NCT03037086 still recruiting?

NCT03037086 is currently completed. Last updated 28 February 2018.

Last reviewed 2018-02-28 · How we verify

NCT03037086: MEDI-APEX

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Asia PDL1 Study Among NSCLC Patients

Completed Last updated 28 February 2018

What this trial tests

trial in Locally Advanced or Metastatic NSCLC in 658 participants. Completed in 27 February 2017.

Timeline

15 October 2015

Primary endpoint
27 February 2017

27 February 2017

Quick facts

Lead sponsor	AstraZeneca
Status	Completed
Study type	OBSERVATIONAL
Enrollment	658
Start date	15 October 2015
Primary completion	27 February 2017
Estimated completion	27 February 2017
Sites	4 locations across China, Japan, South Korea

Conditions studied

Locally Advanced or Metastatic NSCLC — all drugs for Locally Advanced or Metastatic NSCLC →

Sponsor

AstraZeneca — full company profile →

Who can join

18 and older, any sex, with Locally Advanced or Metastatic NSCLC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

MEDI-APEX is a non-interventional, retrospective, cohort study to characterize PD-L1 expression and to assess the clinical characteristics and outcomes among NSCLC patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Locally Advanced or Metastatic NSCLC

Currently open trials in the same condition.

NCT06461156 — A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) · Phase 1 · recruiting
NCT04143607 — ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC · Phase 3 · active not recruiting
NCT03969823 — Whole Genomic Landscape of Advanced EGFR-mutant NSCLC · NA · active not recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03037086 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 28 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03037086.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing